• Innocan Pharma (INNO) updates PCT title as ” Cannabidiol-containing compositions and uses thereof” in the US and EU
  • LPT- CBD-loaded liposomes technology is developing an initial matrix of liposomal formulations of cannabidiol
  • This PCT scope is using Extracellular Vesical (EV), such as exosomes, as a cell delivery platform of cannabinoids for diverse neurological and inflammatory disease
  • Innocan Pharma (INNO) is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer wellness
  • Innocan Pharma (INNO) is down today, trading at C$0.33 as of Sep 21, 3:52 pm ET

Innocan Pharma (INNO) updates PCT title as ” Cannabidiol-containing compositions and uses thereof” in the US and EU.

This PCT scope is using Extracellular Vesical (EV), such as exosomes, as a cell delivery platform of cannabinoids for diverse neurological and inflammatory diseases. This application reflects a fruitful collaboration with Tel-Aviv University. Entering the national phase is one of the major milestones in a patent lifecycle. By entering US and EU, Innocan will have the possibility to protect its pharmaceutical products in the major business countries in the world. Innocan is continually expanding its IP portfolio by filing and prosecuting additional patents in the EV-cannabinoids field that will strengthen its ability to support diverse pharmaceutical products under development.

LPT- CBD-loaded liposomes technology is developing an initial matrix of liposomal formulations of cannabidiol. The company is also reporting successful completion of the CBD liposome physicochemical characterizations and preclinical trials in dogs with osteoarthritis and refractory epilepsy.

CLX – CBD loaded exosomes work is continuing with production, characterization, synthesis of cannabinoids and loading of the cannabinoids to the exosome.

Innocan’s Intellectual Property portfolio contains 12 patent families. 7 patents in the cosmetic category. 2 patents in the liposomes cannabinoids. 3 patents in exosome-cannabinoids synergism.

Innocan continues to expand its brand portfolio and build brand awareness for its Shir, R&G and Synony’s product lines.

LPT – CBD Loaded Liposome Platform – Innocan’s strategy for LPT drug development composes of two verticals: (i) initiate collaboration with an Animal Health Pharmaceutical company to be the first CBD registered drug for companion animal treatment; and (ii) continue expanding human data targeting Phase 1 stage of drug development process followed by a collaboration with Pharma companies for following stages of the development of a human registered drug.

CLX – CBD loaded Exosomes – Innocan is in preparation for the production of the CLX, In-Vivo (animal study) and Safety in animals (including Pharmacokinetic, toxicity, bio-distribution) during 2023. 

Derma Cosmetics Innocan is expanding its distribution to the North American market. The Company is continuing to support its existing distributors in the European market with new product launches and marketing efforts.

Innocan Pharma (INNO) is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer wellness.

Innocan Pharma (INNO) is down today, trading at C$0.33 as of Sep 21, 3:52 pm ET.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

GameStop stock struggles on weak Q4 2023 performance

GameStop Corp. (NYSE:GME) stock struggles after reporting weak Q4 2023 financial results, but it eventually claws back some gains.

Organigram looks to raise capital as cannabis stocks surge

Organigram (TSX:OGI), one of Canada's first cannabis stocks, announces an overnight marketed public offering of units for up to C$25 million.